New research has shown that advanced, hormone-resistant prostate cancer cells can now be killed with the help of a new-targeted therapy that has stopped tumor growth in animals.
Lead investigator Shuk-mei Ho, PhD, chairwoman of the Department of Environmental Health at the University of Cincinnati and her team previously found they can inhibit the growth of prostate cancer cell lines in culture by targeting and activating a protein called G protein-coupled receptor 30 (GPR30) using the experimental drug G-1, a GPR30 agonist, or stimulator.
In their new study, Ho and her co-workers tested G-1 in an animal model of castration-resistant prostate cancer. They implanted human prostate cancer cells beneath the skin of male mice. The established tumor regressed upon castration and after the cancer relapsed, they injected the mice with a low dose of G-1.
"Surprisingly, G-1 was highly effective in halting the growth of the tumors that re-emerged after castration," Ho said.
The castration-resistant tumors showed a 65 percent death of tumor cells necrosis, reports Newswise.
"These results mean G-1 won't work without androgen deprivation therapy," Ho said.
The study will be presented at The Endocrine Society's 93rd Annual Meeting in Boston.